Importance Steroidal mineralocorticoid receptor antagonists, when added to a renin-
angiotensin system blocker, further reduce proteinuria in patients with chronic kidney
disease but may be underused because of a high risk of adverse events. Objective To
evaluate the safety and efficacy of different oral doses of the nonsteroidal mineralocorticoid
receptor antagonist finerenone, given for 90 days to patients with diabetes and high or very
high albuminuria who are receiving an angiotensin-converting enzyme inhibitor or an …